Alerta

COMPOSITIONS AND METHODS FOR INHIBITING DNMT1 METHYLATION ACTIVITY FOR REDUCING CHEMOTHERAPY INDUCED AMPLIFICATION AND REARRANGEMENT IN MIXED LINEAGE LEUKEMIA (MLL)

Absstract of: WO2026025099A1

Compositions and methods for control of DNMT1-mediated site-specific copy gains and genomic insertions associated with mixed lineage leukemia are provided.

MUTATION AND CELL STATE COOPERATION DRIVES PROGRESSION AND IS A TARGETABLE FEATURE OF REMISSION IN ACUTE LYMPHOBLASTIC LEUKEMIA

Absstract of: WO2026024988A1

Methods for treating leukemia are disclosed based on detecting specific cell states and transcriptional programs within leukemic cells. This disclosure presents a novel therapeutic method for treating acute lymphoblastic leukemia (ALL), including BCR-ABL positive and BCR-ABL1-like ALL subtypes. The method involves detecting specific cell states and transcriptional programs in patient samples and administering targeted therapies based on these characteristics. For a pre-B cell-like state or pre-BCR signaling program, a combination of tyrosine kinase inhibitor (TKI) and SYK inhibitor is used. Conversely, a progenitor-like state or stress-autophagy program is treated with a TKI and a p38 MAPK inhibitor. This approach aims to improve treatment efficacy by tailoring therapy to the leukemia's unique molecular and cellular features, particularly in relapsed cases or when minimal residual disease is present.

NUCLEIC ACIDS AND PHARMACEUTICAL COMPOSITIONS FOR IMMUNE CELL ENGAGERS

Absstract of: WO2026025111A1

The present disclosure relates to novel nucleic acids for an immune cell engagers, comprising a ribonucleic acid of formula I: R1 - SP - R2 - R3 - R4 - R5 (I), where R1 is a 5' untranslated region (UTR); SP encodes a signal peptide; R2 encodes a first single chain variable fragment (scFv) that binds a first extracellular protein or a variable region of a heavy chain (VH-only) that binds a first extracellular protein; R3 encodes a second scFv that binds a second extracellular protein; R4 encodes a half-life extender; R5 is a 3'UTR, and where R1 to R5 are oriented 5' to 3', for the treatment of cancers, including but not limited to hematological cancers, including multiple myeloma.

ENABLE DISCOVERY OF BCL-2 FAMILY INHIBITORS TARGETING MODE II COMPLEXES

Absstract of: WO2026025080A1

This application generally relates to pro-survival complex between a guardian and an effector assembled from their intact BCL-2 globular core domains. In particular, the disclosure relates to methods of identifying modulators of BCL2 antagonist/killer (BAK) binding of Myeloid cell leukemia-1 (MCL-1).

TREATMENT OF MULTIPLE MYELOMA

Absstract of: US20260027084A1

The present disclosure provides methods of treating multiple myeloma in a patient in need thereof comprising administering a gamma secretase and a B-cell maturation antigen (BCMA)-directed therapy to the patient.

USE OF A FBXO42 SPECIFIC INHIBITOR IN TREATING NOTCH SIGNALING-DEPENDENT DISEASE

Absstract of: US20260023068A1

The present invention refers to a method for treating Notch signaling-dependent disease in the subject with a FBXO42 specific inhibitor. The Notch signaling-dependent disease is selected from leukemia. Also provided is a method for screening a drug treating Notch signaling-dependent disease using FBXO42 as a target.

IKZF2 AND CK1-ALPHA DEGRADING COMPOUNDS AND USES THEREOF

Absstract of: US20260021103A1

Provided herein are compounds that promote targeted degradation of IKZF1, IKZF2, GSPT1, and/or CK1a, proteins whose activities are implicated in the pathology of certain cancers (e.g., acute myeloid leukemia). Also provided are pharmaceutical compositions comprising the compounds. Also provided are methods of treating cancer, and methods of promoting the degradation of IKZF1, IKZF2, GSPT1, and/or CK1a in a subject or biological sample by administering a compound or composition described herein.

COMBINATIONS OF HISTONE DEACETYLASE INHIBITORS AND IMMUNOMODULATORY DRUGS

Absstract of: US20260021093A1

The invention relates to combinations comprising an HDAC inhibitor and an immunomodulatory drug for the treatment of multiple myeloma in a subject in need thereof. The combinations may, optionally, further comprise an anti-inflammatory agent, such as dexamethasone. Also provided herein are methods for treating multiple myeloma in a subject in need thereof comprising administering to the subject an effective amount of one of the above combinations.

METHODS OF USING ANTI-CD79b IMMUNOCONJUGATES TO TREAT FOLLICULAR LYMPHOMA

Absstract of: US20260021088A1

Provided herein are methods of treating B-cell proliferative disorders (such as Follicular Lymphoma “FL”) using immunoconjugates comprising anti-CD79b antibodies in combination with an immunomodulatory agent (such as lenalidomide) and an anti-CD20 antibody (such as obinutuzumab or rituximab).

COMBINATION THERAPIES FOR THE TREATMENT OF CD33-POSITIVE HEMATOLOGICAL MALIGNANCIES HARBORING MUTATIONS

Absstract of: AU2024283114A1

Provided are methods for treating CD33-positive hematological malignancies, such as acute myelogenous leukemia (AML) and myelodysplastic syndrome (MDS), harboring mutations such as FLT3, IDH1, IDH2, NMP1, and/or MLL1 gene mutations, using combination therapy that includes one or both of a radiolabeled CD33-targeting agent and a drug-conjugated CD33-targeting agent, and one or more targeted therapies, such as FLT3, IDH and Menin inhibitors.

COMPOUNDS THAT RE-ACTIVATE MUTANT P53

Absstract of: AU2024275892A1

The present disclosure is concerned with compounds that restore p53 activity and methods of using the compounds in the treatment of various disorders related to loss of p53 activity such as, for example, cancer (e.g, a sarcoma, a carcinoma, a head-and-neck cancer, hematological cancer, a solid tumor, breast cancer, cervical cancer, gastrointestinal cancer, colorectal cancer, brain cancer, skin cancer, prostate cancer, ovarian cancer, thyroid cancer, testicular cancer, pancreatic cancer, liver cancer, endometrial cancer, melanoma, a glioma, leukemia, lymphoma, chronic myeloproliferative disorder, myelodysplastic syndrome, myeloproliferative neoplasm, non-small cell lung carcinoma, small cell lung carcinoma, renal cancer, lung cancer, colon cancer, cervical cancer, and plasma cell neoplasm (myeloma)). This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.

CLL1-CAR-T CELL, AND PREPARATION METHOD THEREFOR AND USE THEREOF

Absstract of: AU2024284994A1

Disclosed in the present invention are a CLL1-CAR-T cell, and a preparation method therefor and the use thereof. The CLL1-CAR-T cell contains a chimeric antigen receptor, wherein the chimeric antigen receptor comprises a single domain antibody, a hinge region, a transmembrane region and an intracellular signaling region, and the single domain antibody has an amino acid sequence of positions 22-150 of SEQ ID No. 1. The CLL1-VHH-1 CAR-T cell of the present invention can secrete T cell specific effector molecule IFN-γ to specifically kill CLL1+ target cells, inhibit the proliferation of tumor cells in mice, prolong the survival time of mice, and can be used for immunotherapy of diseases associated with CLL1 target (such as acute myelogenous leukemia).

PRALATREXATE AND COP COMBINATION FOR THE TREATMENT OF PATIENTS WITH PERIPHERAL T CELL LYMPHOMA

Absstract of: AU2024296708A1

Methods for treating peripheral T-cell lymphoma include administering to a subject a combination of Cyclophosphamide, Vincristine, Prednisone, and Pralatrexate, wherein the combination does not include doxorubicin. The treatment may be administered in repeated three-week cycles, optionally including a drug holiday.

Methods of treating WHSC1-overexpressing cancers by inhibiting SETD2

Absstract of: AU2025283528A1

The present disclosure provides methods and pharmaceutical compositions for treating or slowing the progression of cancers that overexpress the histone methyltransferase WHSC1, e.g., t(4;14) multiple myeloma, by administering to a subject in need thereof a therapeutically effective amount of an inhibitor of the histone methyltransferase, SETD2. ec e c

N-DESMETHYL RUBOXISTAURIN AS A CDK4/6 INHIBITOR FOR THERAPEUTIC USE IN CANCER

Absstract of: WO2026020038A1

Aspects of this invention are related to the use of N-desmethyl ruboxistaurin and pharmaceutically acceptable formulations thereof to modulate CDK4/6 signaling. The invention encompasses methods for administering N-desmethyl ruboxistaurin to subjects in need, particularly those with a history of cancer or currently experiencing breast cancer, liposarcoma, lung cancer, glioblastoma, melanoma, pancreatic cancer, prostate cancer, colon cancer, ovarian cancer, colorectal cancer, bladder cancer, hepatocellular carcinoma, osteosarcoma, germ cell tumors, advanced solid tumors, lymphoma, leukemia and other hematologic malignancies. The disclosed methods extend beyond disease treatment, including supportive care during radiation chemotherapy and prevention of cancer relapse. N-desmethyl ruboxistaurin administration, alone or in combination with other cancer therapies, is effective in modulating CDK4/6 signaling while mitigating toxicity associated with other treatments.

MOLECULES THAT BIND TO CS1 POLYPEPTIDES

Absstract of: WO2026020037A1

This document provides methods and materials involved in binding a molecule (e.g., an antibody domain, an antigen binding fragment, an antibody, a chimeric antigen receptor (CAR), a cell engager, or an antibody-drug conjugate (ADC)) to a CS1 polypeptide. For example, this document provides binders (e.g., antibody domains, antigen binding fragments, antibodies, CARs, cell engagers, and ADCs) that bind to a CS1 polypeptide and methods and materials for using such binders (or cells expressing such binder such as a cell expressing a CAR) to treat cancer (e.g., multiple myeloma).

N-DESMETHYL RUBOXISTAURIN AS A RSK INHIBITOR FOR THERAPEUTIC USE

Absstract of: WO2026020045A1

Aspects of this invention are related to the use of N-desmethyl ruboxistaurin and pharmaceutically acceptable formulations thereof to modulate RSK signaling. Some aspects of the invention relate to the use of N-desmethyl ruboxistaurin to inhibit RSK. Some aspects of the invention provide methods of using N-desmethyl ruboxistaurin in the treatment of subjects with cancer, including breast cancer, ovarian cancer, prostate cancer, lung cancer, hepatocellular carcinoma, colorectal cancer, melanoma, osteosarcoma, myeloproliferative neoplasms, leukemia, and bladder cancer. The disclosed methods extend beyond disease treatment, including supportive care during radiation chemotherapy and prevention of cancer relapse. N-desmethyl ruboxistaurin administration, alone or in combination with other cancer therapies, inhibits RSK and shows a safety profile that supports its long-term use.

METHODS FOR TREATING MULTIPLE MYELOMA

Absstract of: AU2024283100A1

Embodiments of the present invention relate to methods of treating multiple myeloma in a subject in need thereof, comprising administering therapeutically effective amounts of a GPRC5DxCD3 bispecific antibody on a monthly dosing schedule.

SYSTEM AND METHOD FOR MEASURING AND ANALYZING MINIMAL RESIDUAL DISEASE IN CHILDHOOD B-PRECURSOR ACUTE LYMPHOBLASTIC LEUKEMIA BY MULTIPARAMETER FLOW CYTOMETRY

Absstract of: WO2026017796A1

The present invention relates to a system and a method for measuring and analyzing minimal residual disease (MRD) in pediatric B-cell precursor acute lymphoblastic leukemia (B-ALL) using multiparameter flow cytometry (MPFC). The invention finds application in clinical diagnostics and hematology-oncology for quantifying MRD in B-ALL patients with high sensitivity and specificity, needed for risk stratification, monitoring treatment response, and informing therapeutic decisions. The system comprises interconnected subsystems including an acquisition subsystem with an MPFC instrument, a control and file generation subsystem, and an analytical subsystem. The analytical subsystem incorporates modules for sequential data reduction, automated data cleaning, automated unsupervised data clustering, and interactive cluster analysis. Key advantages include high MRD detection sensitivity (e.g., 10⁻⁵ or 0.001%) and high specificity, without reliance on reference samples or supervised machine learning models, making it applicable in laboratories with different measuring equipment and using different panels of antibodies for identification of leukemic cells.

PANELS AND REAGENT KITS FOR MINIMAL RESIDUAL DISEASE MEASUREMENT IN PEDIATRIC B-CELL PRECURSOR ACUTE LYMPHOBLASTIC LEUKEMIA VIA IMMUNOPHENOTYPING

Absstract of: WO2026017800A1

The present invention relates to a reagent panels for the measurement of minimal residual disease (MRD) associated with pediatric B-cell precursor acute lymphoblastic leukemia (B- ALL) by multiparametric flow cytometry. The reagent panel of the invention comprises a combination of antibodies directed against markers, wherein the combination of antibodies comprises i) antibodies targeting markers CD45, CD20, CD34, CD38, CD10, CD58, CD66c, CD73, CD81, CD123, CD304, CD44, CD86, CD99 and CD371, and ii) antibodies targeting markers CD19 and/or CD22, wherein the antibodies are conjugated with fluorochromes. The invention further relates to the use of said panels for detecting MRD associated with B-ALL and/or for identifying a subject at risk of developing B-ALL relapse. The invention also relates to methods of detecting MRD associated with B-ALL. Key advantages of the invention include achieving high MRD detection sensitivity (e.g., 10⁻⁵ or 0.001%) and high specificity.

1H-PYRROLE-2-AMIDE DERIVATIVE AND USE THEREOF

Absstract of: EP4682142A1

The present invention relates to the field of chemical medicines. Disclosed are a 1H-pyrrole-2-amide derivative and a use thereof. In order to obtain a specific inhibitor for an m6A-modified RNA reader protein YTHDC1 of AML, the present invention provides a 1H-pyrrole-2-amide derivative as shown in formula I, wherein said derivative has high inhibitory activity against YTHDC1. In-vitro experiments prove that said derivative can effectively inhibit the proliferation of acute myeloid leukemia cells, significantly arrest a cell cycle of the acute myeloid leukemia cells in the G0/G1 phase, and induce differentiation and apoptosis of the acute myeloid leukemia cells. A compound and a salt thereof or a pharmaceutical composition of the 1H-pyrrole-2-amide derivative of the present invention provide new options for antitumor drug development targeting YTHDC1 in the art, and have good application prospects.

SYSTEMS AND METHODS FOR CELL OF ORIGIN DETERMINATION FROM VARIANT CALLING DATA

Absstract of: EP4682889A2

The present invention relates generally to classification of biological samples, and more specifically to cell of original classification. In particular, some embodiments of the invention relate to diffuse large B cell lymphoma cell of origin classification using machine learning models. The machine learning models can be based on decision trees such as a random forest algorithm or a gradient boosted decision tree. Features for the models can be determined through analysis of variant data from plasma or blood samples from a plurality of subjects with the disease.

GPRC5D x CD28 Bispecific Antibodies and Methods of Use Thereof

Absstract of: US20260014252A1

The present disclosure provides bispecific antigen-binding molecules comprising a first antigen-binding domain that binds specifically to GPRC5D and a second antigen-binding domain that binds specifically to CD28. In certain embodiments, the antigen-binding molecules are bispecific antibodies or antigen-binding fragments thereof that comprise a first antigen-binding domain that binds specifically to GPRC5D and a second antigen-binding domain that binds specifically to CD28. In certain embodiments, the bispecific antibodies are useful for treating a cancer (e.g., multiple myeloma).

GPRC5D X CD28 BISPECIFIC ANTIBODIES AND METHODS OF USE THEREOF

Absstract of: WO2026015729A1

The present disclosure provides bispecific antigen-binding molecules comprising a first antigen-binding domain that binds specifically to GPRC5D and a second antigen-binding domain that binds specifically to CD28. In certain embodiments, the antigen-binding molecules are bispecific antibodies or antigen-binding fragments thereof that comprise a first antigen-binding domain that binds specifically to GPRC5D and a second antigen-binding domain that binds specifically to CD28. In certain embodiments, the bispecific antibodies are useful for treating a cancer (e.g., multiple myeloma).

USE OF LEUKEMIA-DERIVED CELLS IN OVARIAN CANCER VACCINES

Nº publicación: US20260014255A1 15/01/2026

Applicant:

MENDUS B V [NL]
MENDUS B.V

Absstract of: US20260014255A1

The present disclosure provides methods for treating a progressive ovarian cancer using an allogeneic leukemia-derived cell. Also provided are immunogenic compositions comprising an allogeneic leukemia-derived cell, and pharmaceutical compositions and formulations thereof.